



(51) International Patent Classification:

C07K 16/28 (2006.01) A61K 39/395 (2006.01)
A61P 37/00 (2006.01)

(21) International Application Number:

PCT/US2022/012317

(22) International Filing Date:

13 January 2022 (13.01.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/137,089 13 January 2021 (13.01.2021) US
63/274,748 02 November 2021 (02.11.2021) US

(71) Applicant: **VISTERRA, INC.** [US/US]; 275 2nd Avenue,
4th Floor, Waltham, MA 02451 (US).

(72) Inventors: **VISWANATHAN, Karthik**; C/o Visterra,
Inc., 275 2nd Avenue, 4th Floor, Waltham, MA 02451 (US).
BOOTH, Brian; C/o Visterra, Inc., 275 2nd Avenue, 4th

Floor, Waltham, MA 02451 (US). **RAMAKRISHNAN, Boopathy**; C/o Visterra, Inc., 275 2nd Avenue, 4th Floor, Waltham, MA 02451 (US). **WOLLACOTT, Andrew**; C/o Visterra, Inc., 275 2nd Avenue, 4th Floor, Waltham, MA 02451 (US). **BABCOCK, Gregory**; C/o Visterra, Inc., 275 2nd Avenue, 4th Floor, Waltham, MA 02451 (US). **SHRIVER, Zachary**; C/o Visterra, Inc., 275 2nd Avenue, 4th Floor, Waltham, MA 02451 (US).

(74) Agent: **KIM, Sang-A**; Proskauer Rose LLP, One International Place, Boston, MA 02110 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,

(54) Title: HUMANIZED COMPLEMENT 5A RECEPTOR 1 ANTIBODIES AND METHODS OF USE THEREOF




FIG. 1

(57) Abstract: The present disclosure provides, among other things, two different formats of humanized antibodies against human complement component 5a receptor 1. The disclosure also provides a method of treating a subject having dysfunctions of C5a/C5aR1 axis pathway, including but not limited to ANCA-associated vasculitis, comprising administering to the subject in need thereof an effective amount of antibody or a nucleic encoding an antibodies binding to C5aR1 described herein, and wherein administering results in a decrease in symptoms associated with C5a/C5aR1 associated dysfunction in the subject.

[Continued on next page]



SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*